The clinical trial is designed to evaluate the safety, efficacy, and overall benefit of SurVaxM in patients with newly diagnosed glioblastoma who receive standard-of-care treatment combined with SurVaxM.
MimiVax, Inc., a leader in clinical-stage pharmaceutical research, announced that its now fully enrolled Phase 2b clinical trial of SurVaxM in glioblastoma, has successfully progressed following the first interim analysis of trial data. The analysis, conducted as part of the company’s rigorous clinical development program, has provided valuable insights that support the continued advancement of the trial. The purpose of this study is to determine whether adding SurVaxM to standard-of-care (resection, radiation/chemotherapy) is better than standard treatment alone for patients with newly diagnosed glioblastoma.
While the company is unable to disclose specific details about the interim analysis due to regulatory requirements set forth by the U.S. Food and Drug Administration (FDA), MimiVax remains confident in the potential of SurVaxM and is committed to advancing the study as planned.
Health Technology Insights: Telix Completes Acquisition of Next-Generation Therapeutic Assets
“Clinical trial of SurVaxM in glioblastoma has successfully progressed following interim analysis.“
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said Dr. Michael Ciesielski, CEO of MimiVax. “We are working closely with the FDA to ensure compliance with regulatory guidelines as we move forward with the trial.”
Based on the results of the recent interim futility analysis, and ongoing review by the study’s Independent Data Safety Monitoring Committee, the SURVIVE trial will continue as designed without modification.
Health Technology Insights: Court Square Capital Partners and WindRose Health Investors Announce Joint Investment in Soleo Health
The clinical trial is designed to evaluate the safety, efficacy, and overall benefit of SurVaxM in patients with newly diagnosed glioblastoma who receive standard-of-care treatment combined with SurVaxM at 11 participating major Cancer Centers in the United States. The company will provide updates at appropriate milestones, in accordance with regulatory requirements.
MimiVax thanks all participants, healthcare professionals, clinical support teams and investigators involved in the study for their continued support and commitment to the advancement of SurVaxM.
Health Technology Insights: The Cigna Group Launches Actions To Drive Positive Change for Customers and Patients
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source: PR Newswire
